Skip to content
Screener

Onto Innovation ONTO Business Segments — Restructuring Expenses1

Similar metrics at other companies

Theravance Biopharma logo
TBPHSingle Reportable — Restructuring And Related Expenses
$3.63M
Latham Group, Inc. logo
SWIMSingle Reportable Segment — Restructuring Charges
$0-100%
Alumis Inc. logo
ALMSSingle Reportable — Operating Expenses
$100.15M-15.8%
Immunome logo
IMNMSingle Reportable — Operating Expenses
-$59.33M-24.7%
LQD
LQDASingle Reportable — Program Expenses
$21.66M+64.4%
Theravance Biopharma logo
TBPHSingle Reportable — Operating Expenses
$27.18M-8.9%

Other financials

Income statement

See full
Revenue$343.1M+35.3%
Gross profit$183.3M+50.1%
Operating income$63.6M+97.1%
Net income$60.1M+75.8%
EPS (diluted)$1.21+75.4%

Balance sheet

See full
Cash & equivalents$1.3B+476%
Total debt$17.5M+15.3%
Total equity$1.9B-2.1%
Total assets$3.7B+72.8%

Cash flow

See full
Operating cash flow$61.5M+6.2%
CapEx$3.7M-73.4%
Free cash flow$57.9M+31.0%

Valuation

See full
Market cap$13.73B+212%
P/E84.6×+58.6×
P/S12.3×+8.0×

Profitability

See full
Gross margin50.4%-1.2pp
Operating margin12%-6.4pp
Net margin14.5%-1.8pp
FCF margin22.5%-0.5pp

Returns & leverage

See full
Return on equity8.3%-0.6pp
Debt / equity0.0×
Current ratio9.7×+0.1×

Where this comes from

Reported directly by Onto Innovation in its filing.

Tagged under the XBRL concept onto:RestructuringExpenses1.

The source filing: Onto Innovation’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:04 PM EST
Fiscal year
FY2025
Accession
0001193125-26-066937
Line itemYear Ended / January 3,2026Year Ended / December 28,2024Year Ended / December 30,2023
Adjusted sales and marketing (2)69,95575,91061,604
Adjusted general and administrative (3)90,73676,68766,735
Other segment items:
Restructuring and other (4)63,38923,07710,599
Merger and acquisitions related (4)19,6017,6532,607
Litigation (4)2711,337
Amortization39,40949,43754,823
Operating income132,927187,103116,078

Item 16. Form 10-K Summary.

FAQ

What is Onto Innovation's business segments — restructuring expenses1?
Onto Innovation (ONTO) reported business segments — restructuring expenses1 of $15.85M in Q4 2025.
How has Onto Innovation's business segments — restructuring expenses1 changed year-over-year?
Onto Innovation's business segments — restructuring expenses1 increased by 174.7% year-over-year, from $5.77M to $15.85M.
What is the long-term trend for Onto Innovation's business segments — restructuring expenses1?
Over 2 years (2023 to 2025), Onto Innovation's business segments — restructuring expenses1 has grown at a 144.6% compound annual growth rate (CAGR), from $10.6M to $63.39M.
What does business segments — restructuring expenses1 mean?
Reflects costs incurred from organizational changes, such as workforce reductions or facility consolidations, intended to improve long-term operational efficiency. These are non-recurring in nature and are excluded from core operating performance metrics.

Ask your AI about Onto Innovation's business segments — restructuring expenses1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude